New spin-off to improve biomarkers for unmet medical needs

The Helmholtz Zentrum München project “Metaron Diagnostics“ receives support and funding from Helmholtz Enterprise for the first steps towards a spin-off. The goal is to prepare Metaron Diagnostics’ biomarker assays for clinical validation and launch as in vitro diagnostic (IVD) kit products.

Biomarkers saving lives

Human metabolism reflects processes of health and disease. There are specific biomarkers, which depict different stages of diseases - for example in Chronic Kidney Disease (CKD) or Endometriosis: CKD is one of the most common and severe complications of diabetes and hypertension. CKD increases the risk of cardiovascular disease and myocardial infarction, and end-stage renal disease is lethal unless treated by complex and expensive interventions like dialysis or kidney transplantation. Endometriosis, a chronic condition of unclear etiology characterized by the growth of endometrium outside the uterus, affects up to 10% of the women in the reproductive age. Endometriosis manifests by sometimes severe menstrual pain, infertility, and further complications like inflammation or even cancer.

Prof. Dr. Jerzy Adamski, head of the Research Unit Molecular Endocrinology and Metabolism at Helmholtz Zentrum München, and Klaus Weinberger (sAnalytiCo, Belfast, and UMIT, Hall), and their collaborators developed new diagnostic and prognostic biomarkers for unmet medical needs in nephrology and gynecology. The newly developed diagnostic tools are using the same technology platform, tandem mass spectrometry, to detect disease-specific metabolite patterns, and will support clinical decision-making in defined indications. For CKD, the biomarkers will allow a more practical and reliable selection of kidney transplantation donors, an accurate stratification of CKD patients into the best therapeutic regimens and, eventually, an early risk assessment for patients living with diabetes and hypertension. For endometriosis, the new test will shorten the time to a definitive diagnosis, avoid unnecessary invasive laparoscopies, support the treatment of infertility, and improve quality of life for patients.

Since 1997, 20 spin-offs with around 350 employees have emerged from Helmholtz Zentrum München. Metaron Diagnosticsis part of a bigger Helmholtz Enterprise funding. To learn more about Helmholtz Enterprise and other Helmholtz-start-ups to receive funding, please visit:

We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.